Yong Eun Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yong Eun Park has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Tae Oh Kim
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
11 shared publications - Jin Lee
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
6 shared publications - Byung Chang Kim
Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
5 shared publications - Duk Hwan Kim
Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea
5 shared publications - Hyun Joo Song
Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Korea
5 shared publications - Jae Gon Lee
Department of Internal Medicine, Hanyang University Guri Hospital Hanyang University College of Medicine Guri Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 610-611
Beyond first-line biologic therapy: does treatment sequence matter in ulcerative colitis?
Beyond first-line biologic therapy: does treatment sequence matter in ulcerative colitis?
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 610-611
Open AccessBeyond first-line biologic therapy: does treatment sequence matter in ulcerative colitis?
Beyond first-line biologic therapy: does treatment sequence matter in ulcerative colitis?
- Open Access
- 25 October 2026
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 86 (4) , 477-479
Juvenile Polyposis Syndrome Presenting with Recurrent Hematochezia
Soo-kyung Lee and Yong eun Park. Korean J Gastroenterol 2026;86:477-9. https://doi.org/10.4166/kjg.2026.081
- 25 October 2026
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 86 (4) , 477-479
Open AccessJuvenile Polyposis Syndrome Presenting with Recurrent Hematochezia
Soo-kyung Lee and Yong eun Park. Korean J Gastroenterol 2026;86:477-9. https://doi.org/10.4166/kjg.2026.081
- Open Access
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 307-313
Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms.Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups.Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant.Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms.
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 307-313
Open AccessShort-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms.Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups.Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant.Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms.
- Open Access
- 25 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 575-586
Age-Related Microbial Differences in Newly Diagnosed Crohn’s Disease Reveal the Distinct Enrichment of Oral-Associated Taxa in Pediatric Patients
Crohn's disease (CD) presents differently by age of onset, but the microbial distinctions between pediatric and adult CD are currently unclear. In this study, the gut microbiota of fecal samples collected from newly diagnosed patients with CD (n=88; pediatric 44, adult 44) and their age- and sex-matched healthy controls (HCs, n=112) was analyzed using 16S rRNA gene amplicon sequencing. Differential abundance analysis was performed using MaAsLin2 to identify age-specific microbial signatures, and enterotypes were classified using Dirichlet multinomial mixture modeling. Both pediatric and adult patients with CD exhibited shared dysbiosis characterized by reduced alpha diversity (pEnterobacteriaceae and Enterococcaceae, and depletion of short-chain fatty acid-producing taxa within Ruminococcaceae and Lachnospiraceae. Notably, enterotyping revealed that individuals with CD converged toward a shared, pathobiont-dominated enterotype regardless of age, overriding the age-dependent stratification observed in HCs. Despite this shared convergence, differences in age-stratified comparisons were observed. Adult CD patients exhibited enrichment of resident pathobionts such as Ruminococcus gnavus and Clostridium innocuum, whereas pediatric CD patients exhibited unique and pronounced enrichment of Pasteurellaceae, Neisseriaceae, and Gemellaceae (false discovery rate <0.1). In newly diagnosed patients, CD is characterized by shared dysbiosis and convergence toward a disease-specific enterotype across age groups. However, this was accompanied by distinct microbial features, specifically, the enrichment of taxa previously reported as prevalent in the oral microbiome in children versus resident pathobionts in adults. These findings suggest that age at disease onset is associated with age-stratified differences in microbial profiles in CD.
- 25 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 575-586
Open AccessAge-Related Microbial Differences in Newly Diagnosed Crohn’s Disease Reveal the Distinct Enrichment of Oral-Associated Taxa in Pediatric Patients
Crohn's disease (CD) presents differently by age of onset, but the microbial distinctions between pediatric and adult CD are currently unclear. In this study, the gut microbiota of fecal samples collected from newly diagnosed patients with CD (n=88; pediatric 44, adult 44) and their age- and sex-matched healthy controls (HCs, n=112) was analyzed using 16S rRNA gene amplicon sequencing. Differential abundance analysis was performed using MaAsLin2 to identify age-specific microbial signatures, and enterotypes were classified using Dirichlet multinomial mixture modeling. Both pediatric and adult patients with CD exhibited shared dysbiosis characterized by reduced alpha diversity (pEnterobacteriaceae and Enterococcaceae, and depletion of short-chain fatty acid-producing taxa within Ruminococcaceae and Lachnospiraceae. Notably, enterotyping revealed that individuals with CD converged toward a shared, pathobiont-dominated enterotype regardless of age, overriding the age-dependent stratification observed in HCs. Despite this shared convergence, differences in age-stratified comparisons were observed. Adult CD patients exhibited enrichment of resident pathobionts such as Ruminococcus gnavus and Clostridium innocuum, whereas pediatric CD patients exhibited unique and pronounced enrichment of Pasteurellaceae, Neisseriaceae, and Gemellaceae (false discovery rate <0.1). In newly diagnosed patients, CD is characterized by shared dysbiosis and convergence toward a disease-specific enterotype across age groups. However, this was accompanied by distinct microbial features, specifically, the enrichment of taxa previously reported as prevalent in the oral microbiome in children versus resident pathobionts in adults. These findings suggest that age at disease onset is associated with age-stratified differences in microbial profiles in CD.
- Open Access
- 8 June 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 428-463
Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)
Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)
- 8 June 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 428-463
Open AccessEvidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)
Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID)
- Open Access
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 73-78
Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study
Objectives: Tegoprazan is an alternative to proton pump inhibitors (PPIs). This study evaluated the occurrence of upper gastrointestinal (GI) and cardiovascular (CV) complications in patients with ischemic heart disease undergoing antiplatelet therapy after percutaneous coronary intervention (PCI) who were treated with tegoprazan or PPIs. Methods: Data from 604 patients who received antiplatelet therapy with tegoprazan or PPIs for >6 months after PCI between March 2019 and November 2023 were retrospectively analyzed. The primary GI endpoints were symptomatic gastroduodenal ulcers and upper GI bleeding, while the primary CV endpoints comprised major adverse cardiac events (MACEs), nonfatal myocardial infarction (MI), target vessel revascularization, and death from CV-related causes. Results: Among the 604 patients, 265 received tegoprazan and 339 received PPIs. During a mean follow-up of 17 months, seven patients experienced a GI event (0.4% with tegoprazan vs. 1.8% with PPIs; p=0.112) and 12 experienced MACEs (1.1% with tegoprazan vs. 2.7% with PPIs; p=0.183). Subgroup analysis indicated that target vessel revascularization occurred in six patients, with event rates of 0.8% (n=2) for tegoprazan and 1.2% (n=4) for PPIs (p=0.598). Tegoprazan was associated with similar rates of nonfatal MI (0.8% vs. 2.4%; p=0.125) and death from CV-related causes (0.4% vs. 0%; p=0.258) as PPIs. Conclusions: There were no significant differences in GI- or CV-related complications between patients treated with tegoprazan and those treated with PPIs.
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 73-78
Open AccessClinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study
Objectives: Tegoprazan is an alternative to proton pump inhibitors (PPIs). This study evaluated the occurrence of upper gastrointestinal (GI) and cardiovascular (CV) complications in patients with ischemic heart disease undergoing antiplatelet therapy after percutaneous coronary intervention (PCI) who were treated with tegoprazan or PPIs. Methods: Data from 604 patients who received antiplatelet therapy with tegoprazan or PPIs for >6 months after PCI between March 2019 and November 2023 were retrospectively analyzed. The primary GI endpoints were symptomatic gastroduodenal ulcers and upper GI bleeding, while the primary CV endpoints comprised major adverse cardiac events (MACEs), nonfatal myocardial infarction (MI), target vessel revascularization, and death from CV-related causes. Results: Among the 604 patients, 265 received tegoprazan and 339 received PPIs. During a mean follow-up of 17 months, seven patients experienced a GI event (0.4% with tegoprazan vs. 1.8% with PPIs; p=0.112) and 12 experienced MACEs (1.1% with tegoprazan vs. 2.7% with PPIs; p=0.183). Subgroup analysis indicated that target vessel revascularization occurred in six patients, with event rates of 0.8% (n=2) for tegoprazan and 1.2% (n=4) for PPIs (p=0.598). Tegoprazan was associated with similar rates of nonfatal MI (0.8% vs. 2.4%; p=0.125) and death from CV-related causes (0.4% vs. 0%; p=0.258) as PPIs. Conclusions: There were no significant differences in GI- or CV-related complications between patients treated with tegoprazan and those treated with PPIs.
- Open Access
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiomes
- Vol. 5
Microbiota disparities in stool, oral swabs, and saliva between control and early-onset colorectal neoplasia groups: an exploratory analysis
Background/aim: The increasing incidence of early-age-onset colorectal neoplasia (EAO-CRN) in individuals under 50 years old poses a global health concern. This study aimed to investigate the variations in the microbiota in individuals with EAO-CRN compared with a control group, utilizing stool, oral swab, and saliva samples. Methods: Participants under 50 years of age provided stool, oral swab, and saliva samples. Colorectal neoplasia was classified into the serrated lesions and adenoma–carcinoma groups based on histology and compared with a control group without polyps. The alpha diversity and the taxonomic abundance differences were assessed using amplicon sequence variants obtained through 16S rRNA sequencing and matched taxonomy data. Results: A total of 45 participants were included: 14 in the control, 13 in the serrated lesions, and 18 in the adenoma–carcinoma groups. Microbial analysis revealed no significant differences in the alpha diversity among the groups. However, the stool samples from the serrated lesions group had higher levels of the families Erysipelotrichaceae and Lachnospiraceae compared with the control group. Analysis of the oral swabs indicated relatively elevated levels of the family Streptococcaceae in both the serrated lesions and adenoma–carcinoma groups. In the saliva samples, the serrated lesions and adenoma–carcinoma groups showed higher levels of the family Lactobacillaceae, with the serrated lesions group also exhibiting elevated levels of the family Bifidobacteriaceae. Conclusions: This study elucidates the microbiota changes associated with EAO-CRN, distinguishing between serrated lesions and adenoma–carcinoma groups using stool, oral swab, and saliva samples. These findings contribute to the understanding of the relationship between microbiota and colorectal neoplasia in the early-onset population.
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Microbiomes
- Vol. 5
Open AccessMicrobiota disparities in stool, oral swabs, and saliva between control and early-onset colorectal neoplasia groups: an exploratory analysis
Background/aim: The increasing incidence of early-age-onset colorectal neoplasia (EAO-CRN) in individuals under 50 years old poses a global health concern. This study aimed to investigate the variations in the microbiota in individuals with EAO-CRN compared with a control group, utilizing stool, oral swab, and saliva samples. Methods: Participants under 50 years of age provided stool, oral swab, and saliva samples. Colorectal neoplasia was classified into the serrated lesions and adenoma–carcinoma groups based on histology and compared with a control group without polyps. The alpha diversity and the taxonomic abundance differences were assessed using amplicon sequence variants obtained through 16S rRNA sequencing and matched taxonomy data. Results: A total of 45 participants were included: 14 in the control, 13 in the serrated lesions, and 18 in the adenoma–carcinoma groups. Microbial analysis revealed no significant differences in the alpha diversity among the groups. However, the stool samples from the serrated lesions group had higher levels of the families Erysipelotrichaceae and Lachnospiraceae compared with the control group. Analysis of the oral swabs indicated relatively elevated levels of the family Streptococcaceae in both the serrated lesions and adenoma–carcinoma groups. In the saliva samples, the serrated lesions and adenoma–carcinoma groups showed higher levels of the family Lactobacillaceae, with the serrated lesions group also exhibiting elevated levels of the family Bifidobacteriaceae. Conclusions: This study elucidates the microbiota changes associated with EAO-CRN, distinguishing between serrated lesions and adenoma–carcinoma groups using stool, oral swab, and saliva samples. These findings contribute to the understanding of the relationship between microbiota and colorectal neoplasia in the early-onset population.
- Open Access
- 10 June 2025
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 25 (2) , 172-177
Chronic Eosinophilic Gastritis Presenting as Gastric Outlet Obstruction in a Young Man: A Case Report
Eosinophilic gastritis, a relatively rare condition characterized by eosinophilic infiltration of the gastrointestinal wall, has a chronic course involving relapses and remissions. Herein, we describe the case of a 25-year-old man with chronic eosinophilic gastritis complicated by gastric outlet obstruction. The patient had a history of persistent gastrointestinal symptoms since adolescence and had developed severe dyspepsia and vomiting two months before presentation. Eosinophilic gastritis was confirmed using endoscopy and biopsy. The symptoms improved after steroid treatment, although the mucosal lesions did not completely resolve. This case shows that eosinophilic gastritis can have a chronic course with persistent mucosal lesions, despite symptomatic improvement. Early diagnosis and appropriate treatment of eosinophilic gastritis are important for preventing chronic gastric mucosal changes.
- 10 June 2025
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 25 (2) , 172-177
Open AccessChronic Eosinophilic Gastritis Presenting as Gastric Outlet Obstruction in a Young Man: A Case Report
Eosinophilic gastritis, a relatively rare condition characterized by eosinophilic infiltration of the gastrointestinal wall, has a chronic course involving relapses and remissions. Herein, we describe the case of a 25-year-old man with chronic eosinophilic gastritis complicated by gastric outlet obstruction. The patient had a history of persistent gastrointestinal symptoms since adolescence and had developed severe dyspepsia and vomiting two months before presentation. Eosinophilic gastritis was confirmed using endoscopy and biopsy. The symptoms improved after steroid treatment, although the mucosal lesions did not completely resolve. This case shows that eosinophilic gastritis can have a chronic course with persistent mucosal lesions, despite symptomatic improvement. Early diagnosis and appropriate treatment of eosinophilic gastritis are important for preventing chronic gastric mucosal changes.
- Open Access
- 18 October 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1066
Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Background: Few studies have compared the efficacy and safety of second-line biological therapies in ulcerative colitis (UC) patients with prior exposure to anti-tumor necrosis factor (TNF) therapy. We aim to compare the efficacy and safety between ustekinumab, vedolizumab, and tofacitinib, a current option as second-line biological therapy with different mechanisms in those patients. Methods: This retrospective multi-center study was conducted across five institutions from 2011 to 2022. We enrolled patients with moderate to severe UC who failed anti-TNF therapy and subsequently received ustekinumab, vedolizumab, or tofacitinib as second-line biological therapy. The outcomes were analyzed for clinical response/remission and endoscopic improvement/remission rates after induction therapy, drug persistency, and adverse events. Results: A total of 70 UC patients were included and grouped into ustekinumab (11 patients), vedolizumab (40 patients), and tofacitinib (19 patients) treatments. The clinical response/remission rates after induction therapy were similar between ustekinumab (90.9/81.8%), vedolizumab (92.5/65.0%), and tofacitinib (94.7/73.7%). There were no significant differences in the endoscopic improvement/remission rates between the three groups: 90.9/18.2% for ustekinumab, 72.5/12.5% for vedolizumab, and 84.2/26.3% for tofacitinib. Drug persistence was similar across the three agents (p = 0.130). Three patients of the tofacitinib group experienced adverse events (herpes zoster and hypertriglyceridemia). Conclusions: Based on real-world data, second-line biological therapy with ustekinumab, vedolizumab, and tofacitinib showed comparable efficacy in patients with moderate to severe UC with prior exposure to anti-TNF therapy.
- 18 October 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1066
Open AccessEfficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Background: Few studies have compared the efficacy and safety of second-line biological therapies in ulcerative colitis (UC) patients with prior exposure to anti-tumor necrosis factor (TNF) therapy. We aim to compare the efficacy and safety between ustekinumab, vedolizumab, and tofacitinib, a current option as second-line biological therapy with different mechanisms in those patients. Methods: This retrospective multi-center study was conducted across five institutions from 2011 to 2022. We enrolled patients with moderate to severe UC who failed anti-TNF therapy and subsequently received ustekinumab, vedolizumab, or tofacitinib as second-line biological therapy. The outcomes were analyzed for clinical response/remission and endoscopic improvement/remission rates after induction therapy, drug persistency, and adverse events. Results: A total of 70 UC patients were included and grouped into ustekinumab (11 patients), vedolizumab (40 patients), and tofacitinib (19 patients) treatments. The clinical response/remission rates after induction therapy were similar between ustekinumab (90.9/81.8%), vedolizumab (92.5/65.0%), and tofacitinib (94.7/73.7%). There were no significant differences in the endoscopic improvement/remission rates between the three groups: 90.9/18.2% for ustekinumab, 72.5/12.5% for vedolizumab, and 84.2/26.3% for tofacitinib. Drug persistence was similar across the three agents (p = 0.130). Three patients of the tofacitinib group experienced adverse events (herpes zoster and hypertriglyceridemia). Conclusions: Based on real-world data, second-line biological therapy with ustekinumab, vedolizumab, and tofacitinib showed comparable efficacy in patients with moderate to severe UC with prior exposure to anti-TNF therapy.
- Open Access
- 11 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (41) , e40074
Optimal timeframe for achieving biochemical remission in Crohn’s disease patients treated with first-line biologics: A retrospective multicenter study
Predicting treatment response in Crohn’s disease (CD) patients initiating biological therapy is crucial. The first step involves considering symptom control and normalization of C-reactive protein (CRP). However, data on the actual rates of achieving CRP normalization and the appropriate timeframe are lacking. Therefore, we aim to investigate the rate of attaining CRP normalization and identify its optimal timeframe in CD patients initiating biological therapy. In this retrospective multi-center study, we analyzed moderate to severe CD patients initiating biological therapy from January 2012 to July 2023. The primary outcome was the rate and timeframe for achieving CRP normalization. Secondary outcomes included clinical outcomes in patients who achieved CRP normalization and factors associated with early CRP normalization. Of 183 patients, 123 (67.2%) achieved CRP normalization, with a median duration of 3.8 months (interquartile range 1.4 to 7.4 months). The duration and value difference for CRP normalization between anti-tumor necrosis factor agents, ustekinumab, and vedolizumab were statistically insignificant. Cumulative rates of CD-related hospitalization, intestinal resection, and drug discontinuation over 8 years were 11.4%, 2.4%, and 12.2%, respectively. The duration of CRP normalization correlates with drug discontinuation (area under the curve: 0.64). Treatment with 5-aminosalicylic acid (HR 2.77; 95% confidence interval [CI] 1.26–6.11) and high albumin level (HR 1.64, 95% CI 1.04–2.61) favored early CRP normalization, whereas structuring behavior less likely than inflammatory behavior (HR 0.43, 95% CI 0.19–0.96). We have provided the actual rate of achieving CRP normalization and its appropriate timeframe as an initial target in CD treatment.
- 11 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (41) , e40074
Open AccessOptimal timeframe for achieving biochemical remission in Crohn’s disease patients treated with first-line biologics: A retrospective multicenter study
Predicting treatment response in Crohn’s disease (CD) patients initiating biological therapy is crucial. The first step involves considering symptom control and normalization of C-reactive protein (CRP). However, data on the actual rates of achieving CRP normalization and the appropriate timeframe are lacking. Therefore, we aim to investigate the rate of attaining CRP normalization and identify its optimal timeframe in CD patients initiating biological therapy. In this retrospective multi-center study, we analyzed moderate to severe CD patients initiating biological therapy from January 2012 to July 2023. The primary outcome was the rate and timeframe for achieving CRP normalization. Secondary outcomes included clinical outcomes in patients who achieved CRP normalization and factors associated with early CRP normalization. Of 183 patients, 123 (67.2%) achieved CRP normalization, with a median duration of 3.8 months (interquartile range 1.4 to 7.4 months). The duration and value difference for CRP normalization between anti-tumor necrosis factor agents, ustekinumab, and vedolizumab were statistically insignificant. Cumulative rates of CD-related hospitalization, intestinal resection, and drug discontinuation over 8 years were 11.4%, 2.4%, and 12.2%, respectively. The duration of CRP normalization correlates with drug discontinuation (area under the curve: 0.64). Treatment with 5-aminosalicylic acid (HR 2.77; 95% confidence interval [CI] 1.26–6.11) and high albumin level (HR 1.64, 95% CI 1.04–2.61) favored early CRP normalization, whereas structuring behavior less likely than inflammatory behavior (HR 0.43, 95% CI 0.19–0.96). We have provided the actual rate of achieving CRP normalization and its appropriate timeframe as an initial target in CD treatment.